Body Systems

Stroke11 Results found

Studies recruiting participants:

AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE)

The purpose of this study is to evaluate the Amulet™ device for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial fibrillation.

Recruiting
Principal Investigator 
Jacqueline Saw
Body Locations and Systems 
Stroke, Stroke
Area 
Vancouver
Age 
18 and above

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)

This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment.

Recruiting
Principal Investigator 
Thalia Field
Body Locations and Systems 
Stroke, Stroke
Area 
Vancouver
Age 
18 and above

Closed for recruitment:

Young Embolic Stroke of Undetermined Source Patient Registry (Y-ESUS)

This study seeks to determine the clinical characteristics of young ESUS patients using diagnostic criteria of the Cryptogenic Stroke / ESUS International Working Group, and to determine the rates of stroke recurrence, death, and hospital readmission in a contemporary cohort of young ESUS patient

Closed for Recruitment
Principal Investigator 
Thalia Field
Body Locations and Systems 
Stroke, Stroke
Area 
Vancouver
Age 
21-50

Cognitive Testing in Young Stroke Patients

Participants will complete a series of computerized cognitive tests and two health questionnaires. The performance of young stroke patients will be compared to healthy controls for each computerized cognitive test.

Closed for Recruitment
Principal Investigator 
Thalia Field
Body Locations and Systems 
Stroke, Stroke
Area 
Vancouver
Age 
18-55

RESPECT PFO Clinical Trial

The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.

Closed for Recruitment
Principal Investigator 
Philip A. Teal
Body Locations and Systems 
Stroke
Area 
Vancouver
Age 
18-60